The FDA has approved epcoritamab-bysp (Epkinly) with rituximab and lenalidomide for relapsed or refractory follicular ...
The FDA has approved ziftomenib (KOMZIFTI), the first oral menin inhibitor for adults with relapsed or refractory ...
Novartis has opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California, ...
Results from the phase II LenCabo trial show that lenvatinib plus everolimus significantly prolonged progression-free ...
ESMO’s new ELCAP guidance, published in Annals of Oncology, distills 23 consensus statements from 20 experts to safely ...
Five-year data from the Phase III NATALEE trial confirm that adjuvant ribociclib (Kisqali) plus endocrine therapy reduces ...
New data from the phase 1b DeLLphi-303 study show that adding tarlatamab to first-line chemoimmunotherapy achieved a 71% ...
Findings from the Phase 3 ASCENT-03 trial, presented at ESMO 2025, demonstrated that sacituzumab govitecan (Trodelvy®) ...
ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ONCOLife is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback